In a patient with chronic iron deficiency anemia due to ongoing blood loss, serum iron 48 µg/dL, total iron‑binding capacity 361 µg/dL, transferrin saturation 13 %, and hemoglobin 10.1 g/dL, would intravenous iron infusion still be beneficial?

Yes, this patient would clearly benefit from intravenous iron infusion.

With a transferrin saturation of only 13% (well below the 20% threshold), ongoing chronic blood loss, and hemoglobin at 10.1 g/dL, this patient meets clear criteria for IV iron therapy and should receive it promptly 1.

Why IV Iron is Indicated Here

Your patient's laboratory values paint a textbook picture of iron deficiency requiring intravenous therapy:

• Transferrin saturation of 13% is significantly below the 20% threshold that defines iron deficiency in chronic disease states 2
• Serum iron of 48 µg/dL is low
• TIBC of 361 µg/dL is elevated, indicating the body is desperately trying to capture more iron
• Hemoglobin of 10.1 g/dL represents moderate anemia requiring correction

The 2024 AGA guidelines are explicit: intravenous iron should be used when ferritin levels do not improve with a trial of oral iron, or when the patient has a condition where oral iron is not likely to be absorbed 1. With ongoing chronic blood loss, oral iron is fighting a losing battle—you're trying to fill a bucket with a hole in it.

The Chronic Blood Loss Factor

Ongoing blood loss fundamentally changes the treatment approach. The AGA specifically addresses this: in patients with ongoing bleeding who do not respond to oral iron therapy, IV iron should be used 1. Your patient's chronic blood loss means:

• Iron stores are continuously depleted faster than oral supplementation can replenish them
• The gut can only absorb 1-2 mg of elemental iron per day from oral supplements
• Meanwhile, chronic blood loss can deplete iron stores by several milligrams daily
• This creates a negative iron balance that oral therapy cannot overcome

Expected Benefits

After IV iron infusion, you should see:

• Hemoglobin increase of 1-2 g/dL within 4-8 weeks 3
• Improvement in symptoms (fatigue, exercise intolerance, cognitive function)
• Normalization of iron parameters (target ferritin >50 ng/mL in absence of inflammation, TSAT >20%) 3

Practical Implementation

Choose a high-dose formulation that allows complete iron deficit replacement in 1-2 infusions rather than multiple visits 1. Options include:

• Ferric carboxymaltose (FCM) - 750 mg per dose, typically two doses
• Ferric derisomaltose (FDI) - up to 1000-1500 mg single infusion 3
• Ferumoxytol - 510 mg per dose, typically two doses

Important caveat: Avoid repeated FCM infusions due to risk of treatment-emergent hypophosphatemia 3. Given your patient has chronic blood loss requiring ongoing therapy, FDI may be preferable as it's approved for total dose infusion and doesn't carry the same hypophosphatemia risk.

Monitoring Strategy

Recheck labs 4-8 weeks after the last infusion (not sooner, as circulating iron interferes with assays) 3:

• CBC for hemoglobin response
• Ferritin and transferrin saturation
• If hemoglobin hasn't increased by 1-2 g/dL, investigate other causes of anemia

Address the Underlying Cause

While treating with IV iron, you must simultaneously investigate and address the source of chronic blood loss 1. Common culprits include:

• Gastrointestinal bleeding (angiodysplasia, inflammatory bowel disease, malignancy)
• Heavy menstrual bleeding in women
• Occult bleeding from medications (NSAIDs, anticoagulants)

The AGA emphasizes that endoscopic evaluation and treatment of bleeding sources should accompany iron replacement 1.

Why Not Oral Iron?

While oral iron could theoretically be tried first, it's likely to fail in this scenario because:

• Chronic ongoing losses exceed what oral supplementation can replace
• Many patients with chronic blood loss have underlying GI pathology affecting absorption
• Oral iron causes GI side effects in the majority of patients, leading to poor adherence 4
• The patient's already depleted iron stores (evidenced by low TSAT) need rapid repletion

The bottom line: Don't waste time with oral iron in a patient with ongoing blood loss and moderate anemia—proceed directly to IV iron while investigating the bleeding source.